Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737249) titled 'Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease' on July 27.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Peking Union Medical College Hospital

Condition: Interstitial Lung Diseases

Intervention: Drug: golidocitinib plus corticosteroid

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 1, 2026

Target Sample Size: 60

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/stud...